RNAi Technology Market to Reach USD 9.03 Billion by 2032, Driven by Advances in Gene Silencing and Therapeutic Applications – SNS Insider

GlobeNewswire On November 3, 2025 19:15 IST

SNS Insider report highlights a CAGR of 14.68% from 2025–2032 as RNAi emerges as a transformative force in biotechnology, precision medicine, and agricultural innovation.

Austin, Nov. 03, 2025 (GLOBE NEWSWIRE) — RNAi Technology Market Size & Growth Analysis

According to SNS Insider, the global RNAi Technology Market was valued at USD 3.02 billion in 2024 and is projected to reach USD 9.03 billion by 2032, expanding at a CAGR of 14.68% over 2025–2032. RNA interference (RNAi) technology has emerged as one of the most promising innovations in molecular biology and biotechnology, with high potential in therapeutic, agricultural, and research applications.

Growing investment in RNAi-based therapeutics, improvements in delivery systems, and breakthroughs in precision medicine are driving global market growth. In agriculture, RNAi is establishing itself as a renewable and environmentally safe alternative to pesticides, while in human health, it is revolutionizing treatment for neurological and genetic diseases.

Get free Sample Report of RNAi Technology Market: https://www.snsinsider.com/sample-request/6921

RNAi Technology Market Overview:

RNA interference (RNAi) is a natural process in which RNA molecules control the function of specific genes by inactivating them. This technology has been instrumental in regulating pathogenic genes. RNAi drugs are currently in advanced stages of clinical trials for disorders such as Huntington’s disease, epilepsy, and geographic atrophy.

The technology has also shown potential in agriculture. According to a 2025 study, the incidence of Varroa destructor mites in honeybees was reduced by 42% by feeding them dsRNA. This provides a sustainable solution for pest control without harming bees. RNAi technology is expanding its role in biology, providing an important foundation for next-generation therapeutics and environmentally friendly agricultural practices.

Major Players in the RNAi Technology Market Include:

Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Novo Nordisk A/S
Silence Therapeutics PLC
Sanofi S.A.
Arbutus Biopharma Corp.
Sirnaomics Ltd.
Benitec Biopharma Ltd.
Phio Pharmaceuticals Corp.
Olix Pharmaceuticals Co. Ltd.
ST Pharm Co. Ltd. and Other Participants

RNAi Technology Market Segment Insights

By Product & Service

The products segment dominated the market in 2024 attributed to the increasing availability and uptake of RNAi-based kits, reagents, and delivery systems for effective gene silencing in research and therapy. The services segment is expected to register the fastest growth in the market over the forecast period. Growing dependence on custom RNAi synthesis, screening services, and gene knockdown studies, particularly among pipeline-oriented companies, is boosting demand for service providers with expertise in the field.

By Application

The drug discovery & development application led the market with 71.7% market share in 2024. The expanded usage of RNAi technology is the most prominent driver in this segment’s leadership position since companies are using this technology for new therapeutic target identification and validation. The functional genomics segment is expected to grow at a significant rate in the coming years. The increasing need to better understand gene function, interactions, and regulatory mechanisms in various organisms will drive demand for RNAi-based functional genomics studies.

By End-use

Pharmaceutical and biotechnology companies comprised the majority share of the market in 2024, with a contribution of 59.5%, largely due to the large amounts of investment in RNAi-based therapeutics development, collaborative research, and licensing agreements using RNAi technology. CROs and CMOs are anticipated to exhibit the highest growth in the RNAi technology market during the forecast period due to the increasing pharmaceutical companies relying on outsourcing models to minimize development time and operational costs.

Need Any Customization Research on RNAi Technology Market, Enquire Now: https://www.snsinsider.com/enquiry/6921

Regional Analysis:

North America dominated the RNAi technology market in 2024 with a 42.2% market share. This is due to the strong research infrastructure of the region, heavy investment in biotechnology and pharmaceutical industries, as well as a liberal regulatory policy.

Asia Pacific is anticipated to be the fastest-growing region during the forecast period, driven by increased healthcare spending, growing biotechnology industries, and heightened awareness of RNAi-based medicines.

Recent Developments:

In May 2024, Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, successfully translated RNA interference (RNAi) research into a groundbreaking class of therapies, transforming the potential of RNAi into impactful new treatments.

Exclusive Sections of the Report (The USPs):

R&D AND CLINICAL TRIAL LANDSCAPE – helps you assess the volume and progress of RNAi-based therapeutic trials globally, providing insights into innovation hotspots, key disease targets, and evolving RNA interference modalities.
FUNDING AND INVESTMENT TRENDS – helps you track venture capital inflows, strategic collaborations, and public–private partnerships driving RNAi technology advancement across pharmaceutical and biotech ecosystems.
PATENT FILINGS AND APPROVAL ANALYSIS – helps you understand the intellectual property momentum, recent approvals, and patent concentration across regions, reflecting innovation density and competitive edge.
REGIONAL ADOPTION AND APPLICATION INSIGHTS – helps you uncover region-specific uptake of RNAi technologies across healthcare, agriculture, and biomedical research, highlighting growth opportunities and infrastructure readiness.
HEALTHCARE AND RESEARCH SPENDING PATTERNS – helps you evaluate regional expenditure on RNAi research, therapeutic development, and institutional adoption to identify high-investment zones and emerging market clusters.

Buy the RNAi Technology Market Report Now: https://www.snsinsider.com/checkout/6921

RNAi Technology Market Report Scope

Report Attributes	Details
Market Size in 2024	USD 3.02 Billion
Market Size by 2032	USD 9.03 Billion
CAGR	CAGR of 14.68% From 2025 to 2032
Base Year	2024
Forecast Period	2025-2032
Historical Data	2021-2023
Key Segments	By Product & Service [Products (miRNA, siRNA, Others), Service] By Application [Drug Discovery & Development, Functional Genomics, Others] By End-use [Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROs & CMOs]
Regional Analysis/Coverage	North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).

Access Complete Report Details of RNAi Technology Market Analysis & Outlook: https://www.snsinsider.com/reports/rnai-technology-market-6921

[For more information or need any customization research mail us at info@snsinsider.com]

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: info@snsinsider.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.